Incidence Trend of Brain Tumors in Iran: A Systematic Review and Meta-analysis

IF 0.4 Q4 ONCOLOGY

International Journal of Cancer Management Pub Date : 2023-06-11 DOI:10.5812/ijcm-136310

Sohrab Sadeghi, Hassan Reza Mohammadi

引用次数: 0

Abstract

Context: Primary brain tumor (PBT) causes poor prognosis and significant complications, which include movement problems such as balance disorders, failed return to work, and daily life activities. Objectives: The aim of the present study is to estimate the prevalence of PBT in Iran, using a meta-analysis method. Methods: This meta-analysis study was conducted in Iran in 2023 and articles published until the beginning of 2023 were included in the study, using the English keywords of brain cancer, brain tumor, tumor prevalence, prevalence, cancer, nervous system cancer, and their Persian equivalents. Data analysis was carried out, using CMA software. Results: After the initial search, 890 articles on BT were found, and 21 eligible articles were included in the meta-analysis. Also, the prevalence of brain cancer is 4% (95%CI: 3.3 - 4.8) in men and 2.9% (95%CI: 2.3 - 3.6) in women. Conclusions: According to the result, the BT incidence rate is 4% for males and 2.9% for females. Therefore, it is necessary to take necessary preventive measures in this regard.

查看原文本刊更多论文

伊朗脑肿瘤发病率趋势:系统回顾和荟萃分析

背景:原发性脑肿瘤(PBT)预后差，并发症严重，包括平衡障碍等运动问题，无法恢复工作和日常生活活动。目的:本研究的目的是利用荟萃分析方法估计伊朗PBT的患病率。方法:这项荟萃分析研究于2023年在伊朗进行，研究纳入了2023年初之前发表的文章，使用的英文关键词是脑癌、脑肿瘤、肿瘤患病率、患病率、癌症、神经系统癌症及其波斯语等效词。采用CMA软件进行数据分析。结果:初步检索后，共检索到890篇关于BT的文章，21篇符合条件的文章被纳入meta分析。此外，男性脑癌患病率为4% (95%CI: 3.3 - 4.8)，女性为2.9% (95%CI: 2.3 - 3.6)。结论:根据研究结果，男性BT发病率为4%，女性为2.9%。因此，有必要在这方面采取必要的预防措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Cancer Management ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.